| Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, ... Nature 592 (7854), 438-443, 2021 | 2710* | 2021 |
| Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1457 | 2021 |
| Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa R Viana, S Moyo, DG Amoako, H Tegally, C Scheepers, CL Althaus, ... Nature 603 (7902), 679-686, 2022 | 1401 | 2022 |
| SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... Nature medicine 27 (4), 622-625, 2021 | 1321* | 2021 |
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ... Nature 509 (7498), 55-62, 2014 | 779 | 2014 |
| The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, ... Journal of virology 85 (10), 4828-4840, 2011 | 591 | 2011 |
| Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape PL Moore, ES Gray, CK Wibmer, JN Bhiman, M Nonyane, DJ Sheward, ... Nature medicine 18 (11), 1688-1692, 2012 | 373 | 2012 |
| New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency NA Doria-Rose, JN Bhiman, RS Roark, CA Schramm, J Gorman, ... Journal of virology 90 (1), 76-91, 2016 | 241 | 2016 |
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals GD Tomaras, JM Binley, ES Gray, ET Crooks, K Osawa, PL Moore, ... Journal of virology 85 (21), 11502-11519, 2011 | 239 | 2011 |
| Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes CK Wibmer, JN Bhiman, ES Gray, N Tumba, SS Abdool Karim, ... PLoS pathogens 9 (10), e1003738, 2013 | 224 | 2013 |
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors ES Gray, N Taylor, D Wycuff, PL Moore, GD Tomaras, CK Wibmer, ... Journal of virology 83 (17), 8925-8937, 2009 | 222 | 2009 |
| Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B. 1.351) T Moyo-Gwete, M Madzivhandila, Z Makhado, F Ayres, D Mhlanga, ... New England Journal of Medicine 384 (22), 2161-2163, 2021 | 161* | 2021 |
| HIV broadly neutralizing antibody targets CK Wibmer, PL Moore, L Morris Current opinion in HIV and AIDS 10 (3), 135-143, 2015 | 161 | 2015 |
| HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens W Fischer, EE Giorgi, S Chakraborty, K Nguyen, T Bhattacharya, J Theiler, ... Cell host & microbe 29 (7), 1093-1110, 2021 | 83 | 2021 |
| Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected … ES Gray, MA Moody, CK Wibmer, X Chen, D Marshall, J Amos, PL Moore, ... Journal of virology 85 (15), 7719-7729, 2011 | 80 | 2011 |
| Emergence and phenotypic characterization of the global SARS-CoV-2 C. 1.2 lineage C Scheepers, J Everatt, DG Amoako, H Tegally, CK Wibmer, A Mnguni, ... Nature Communications 13 (1), 1976, 2022 | 65* | 2022 |
| UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C HT Mufhandu, ES Gray, MC Madiga, N Tumba, KB Alexandre, T Khoza, ... Journal of virology 86 (9), 4989-4999, 2012 | 48 | 2012 |
| Structure and recognition of a novel HIV-1 gp120-gp41 interface antibody that caused MPER exposure through viral escape CK Wibmer, J Gorman, G Ozorowski, JN Bhiman, DJ Sheward, DH Elliott, ... PLoS pathogens 13 (1), e1006074, 2017 | 45 | 2017 |
| Structure of an N276-dependent HIV-1 neutralizing antibody targeting a rare V5 glycan hole adjacent to the CD4 binding site CK Wibmer, J Gorman, CS Anthony, NN Mkhize, A Druz, T York, ... Journal of virology 90 (22), 10220-10235, 2016 | 36 | 2016 |
| Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 S Lertjuthaporn, C Cicala, D Van Ryk, M Liu, J Yolitz, D Wei, F Nawaz, ... PLoS pathogens 14 (8), e1007278, 2018 | 32 | 2018 |
